France-Sale of Uvestérol D suspended after the death of a baby – Boursorama

the

 (Updated with details) PARIS, January 4 (Reuters) - The national security Agency of medicines (MSNA) announced on Wednesday the launch of a procedure of suspension of the marketing in France of the Uvestérol D, a vitamin D intake, "as a precautionary measure" after the death of a new-born on the 21st of December. This baby, a victim of cardio-respiratory arrest, had received a dose of Uvestérol D, frequently administered in France for newborns, infants and children under five years to prevent the risk of rickets and bone demineralization. The MAN explains in a press release that "the findings of investigations available to date highlight a probable link between the deaths and the administration of the Uvestérol D." The minister of Health, Marisol Touraine, has called on the parents to not give the product to their children, and announced the establishment of a toll-free number to strengthen the information of the families. "The minister would like to reassure parents whose c   hildren have received the drug : they will not be harmed. In fact, it is the mode of administration, specific to the product that presents risk (and not the vitamin D)," adds a press release of the ministry of Health. He also points out that only the Uvestérol D is concerned with the procedure of the MAN and not the specialties of vitamin D marketed by other manufacturers. The Uvestérol D is manufactured by the laboratoire Crinex based in the parisian suburbs. Nobody was reachable in the immediate future in Crinex for a comment. According to the MSNA, the Uvestérol D is the object since 2006 enhanced surveillance because of its potential adverse effects. (Eric Faye and Gwénaëlle Barzic, edited by Emmanuel Jarry) 

© 2016 Thomson Reuters. All rights reserved.

Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication gold redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors gold delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.